Dr. Rahul K. Verma
♦ Ph.D., Pharmaceutical Sciences. Pharmaceutics division, Central Drug Research Institute (CDRI), Lucknow, India (2009-2013)
♦ M.S.(Pharm.)., National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India (2003-2005)
♦ B. Pharmacy., Ram-Eesh institute of Technology, Greater NOIDA, India (1999-2003)
♦ Postgraduate Diploma in Intellectual Property Rights- IGNOU, New Delhi (2012)
♦ Scientist-C in Institute of Nano Science and Technology (INST), Mohali, Punjab, India.(April 2014 to Present)
♦ Postdoctoral Researcher- Oklahoma University, Oklahoma City, OK, USA (March 2013- March 2014)
♦Senior Research Fellow- Central Drug Research Institute (CDRI), Lucknow, India (August 2009 to February 2014)
♦ Research Assistant- Central Drug Research Institute (CDRI), Lucknow, India (January 2007 to August 2009)
♦Senior Research Fellow- Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India (September 2005 to November 2006)
◊ Our research is aimed at developing safe, efficient, and clinically viable nanoparticulate delivery systems and biomaterials for receptor based targeting, controlled release and depot effect of therapeutic agents/vaccine to their site of action.
◊ Development of antigen and adjuvant loaded nano-carrier systems for nasal mucosal immunization. Designing of nitric oxide releasing nanocarriers for therapy of infectitious diseases like tuberculosis, leishmaniasis.
◊ Delivery of therapeutic agents for the treatment of lung and systemic diseases via dry powder inhalation (DPIs), particularly for tuberculosis and lung cancer.
◊ In vitro and in vivo evaluation of novel drug delivery platforms, preclinical drug evaluation in cell lines animal models.
◊ Royal Society of United Kingdom Fellowship UK- CSIR, INDIA-2009-10 – received to work in UK at Institute of pharmaceutical Innovation (IPI) Bradford University in year 2009-10.
◊ Director’s Special CDRI incentive award-2008.
◊ Bioencapsulation Research Group (BRG)- France travel Award 2009- received to travel and present at Groningen University, THE NETHERLANDS
◊ Bioencapsulation Research Group (BRG)- France travel Award 2008- received to travel and present at Dublin City University, Dublin, IRELAND.
◊ CSIR-SRF – Qualified Senior Research Fellowship-2009 (Council of Scientific & Industrial Research (CSIR), INDIA.
◊ Post Graduate fellowship from NIPER during MS (Pharm) course (2003-2005)
◊ GATE (Graduate Aptitude Test for Engineering) - Qualified in Pharmaceutical Sciences -2004.organized by Indian Institute of Technology (IIT), INDIA.
- Verma RK and Garcia-Contreras L (2014) In Vitro Comparison of Two Nasal Delivery Devices to Administer Dry Powders. Respiratory drug delivery (accepted)
- Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, Misra A and Fourie PB (2013) Inhaled microparticles containing clofazimine are efficacious in the treatment of experimental tuberculosis in mice. Antimicrobial Agents and Chemotherapy 57(2): 1050-1052 (IF- 4.8)
- Verma RK, Agrawal AK, Singh AK, Mohan M, Gupta A, Gupta P, Gupta UD, Verma PRP, and Misra A. (2013) Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill M. tuberculosis, Tuberculosis, 93 (4):412-7 (IF- 3.47)
- Verma RK, Singh AK, Mohan M, Agrawal AK, Verma PRP, Gupta A and Misra A (2012) Inhalable Microparticles Containing Nitric Oxide Donors: Saying NO to Intracellular Mycobacterium Tuberculosis. Molecular Pharmaceutics. 9(11): 3183-3187. (IF- 5.40).
- Verma RK, Mukker JK, Singh RSP, Kumar K, Verma PRP and Misra A (2012) Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to Rhesus macaques. Molecular Pharmaceutics. 9(4): 1011-1016. (IF- 5.40)
- Verma RK, Kaur J, Kumar K, Yadav AB and Misra A (2008) Intracellular time course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary delivery of inhalable Microparticles to Mice. Antimicrobial Agents and Chemotherapy. 52(9): 3195-3201.
- Verma RK, Pandya S, and Misra A (2011) Loading and Release of Amphotericin-B from Biodegradable Poly (lactic-co-glycolic acid) Nanoparticles Journal Biomedical Nanotechnology. 7: 118-120.
- Verma RK, Singh AK, Mohan M, Agrawal AK, and Misra A (2011) Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug delivery systems. Therapeutic Delivery. 2(6): 753-768.
- Verma RK, Tripathy RK, Paul MK, Nayyar A, Jain R and Mukhopadhayay AK (2013) Bacterial DNA gyrase is not the target of quinoline based anti-tubercular compounds International Research journal of Pharmacy. 4(1): 284-292.
- Singodia D, Verma A,Verma RK, and Mishra PR (2012) Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Application in Drug Delivery. Nanomedicine - Nanotechnology, Biology and Medicine. 8(4): 468-477.
- Pandya S, Verma RK, and Misra A (2011) Nanoparticles Containing Nitric Oxide Donor with Antileishmanial Agent for Synergistic Effect Against Visceral Leishmaniasis. Journal Biomedical Nanotechnology. 7: 213-215
- Dwivedi P, Kansal S, Sharma M, Shukla R, Verma AK, Shukla P, Tripathi P, Gupta PK, Saini D,Verma RK, Dwivedi AK and Mishra PR (2012) Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. Journal of Drug Targeting, 20 (10): 883-96.
- Dubey PK, Singodia D,Verma RK and Vyas SP (2011) RGD modified albumin nanospheres for tumour vasculature targeting, Journal Pharmacy and Pharmacology, 63(1): 33-40
- Yadav AB, Muttil P, Singh, Verma RK, Mohan M and Misra A (2010) The devil's advocacy: When and why inhaled therapies for tuberculosis may not work.Tuberculosis, 9, 65-66
- Kaur J, Muttil P, Verma RK, Kumar K, Yadav AB, Sharma R and Misra A (2008) Apparatus for Pulmonary Delivery of Microparticles as a Dry Powder Inhalation Targeting Lung and Airway Macrophages in Mice. European Journal of Pharmaceutical sciences. 34: 56-65
- Yadav AB, Muttil P, Singh AK, Verma RK, Mohan M, Sinha SK and Misra A (2010) Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis 90: 188-196
- Yadav AB, Sharma R, Muttil P, Singh AK, Verma RK, Mohan M, Patel SK and Misra A (2009) Inhalable Microparticles Containing Isoniazid and Rifabutin Target Macrophages and Stimulate the Phagocyte” to Achieve High Efficacy. Indian journal of Experimental Biology. 469-474
- Verma RK, Kaur J, Yadav AB, Kumar K and Misra A (2008) PLA microparticles for pulmonary delivery of Anti-TB drugs: Biodistribution study. NATURE Preceedings. (Abstract)
- Verma RK and Misra A (2008) Microparticles specific for lung delivery: in-vivo drug distribution in monkeys. NATURE Preceedings. (Abstract)
◊ Verma RK, Ibrahim M, and Garcia-Contreras L. Lung anatomy and physiology and their implications for pulmonary drug delivery, Edited by-Nokhodchi and Martin, Pulmonary drug delivery: Advances and challenges, Wiley press, USA
◊ Singh Ak, Gupta A, Mohan M, Agrawal AK, Verma RK, Sharma R, Misra A Modulation of host pathogen interaction following particle phagocytosis by infected macrophages In: Norazmi Mohd Nor, Armando Acosta and Maria Elena Sarmiento (Eds). The Art and Science of Tuberculosis Vaccine Development. Oxford University Press, UK
◊ Verma RK, Bailey-Downs LC, Kunch A, Bastian A, Hurst RE, Disch BC, Ihnat MA, and Garcia-Contreras L. Pharmacokinetics of DT-310, a novel anticancer compound, in mice. Stephenson Cancer Center Research Symposium 31st January 2014, Oklahoma City , USA
◊ Verma RK, Raghuvanshi D, Bailey-Downs LC, Kunch A, Ihnat MA, and Garcia-Contreras L. Development and validation of a HPLC method to determine concentrations of a novel anti-cancer compound, DT330 in biological samples AAPS annual meeting (10-14 Nov 2013), San Antonio, USA.
◊ Verma RK, I brahim, Raghuvanshi D, Abraham SN, Staats HF, and Garcia-Contreras L. Optimization of Spray Freeze Drying Process Conditions to Prepare West Nile Virus Vaccine for Nasal Immunization AAPS annual meeting (10-14 Nov 2013), San Antonio, USA.
◊ Verma RK and Misra A Augmenting the macrophage nitric oxide response to intracellular Mycobacterium tuberculosis. Conference on Inhaled therapy for tuberculosis (1-3 Oct 2013), Tokyo University of Science, Tokyo JAPAN
◊ UK- Pharm Science-2010- the Academy of Pharmaceutical Sciences of Great Britain, University of Nottinghum, Nottinghum, UNITED KINGDOM(UK) (attended).
◊ Verma RK and Misra A. Microparticles specific for lung delivery: in-vivo drug distribution in monkeys. XVII International conference on Bioencapsulation-2009,Groningen, THE NETHERLANDS.
◊ Verma RK, Kaur J, Yadav AB, Kumar K and Misra A. PLA microparticles for pulmonary delivery of AntiTB drugs: biodistribution study. XVI International conference on Bioencapsulation-2008,Dublin, IRELAND
◊ Kaur J, Verma RK, Yadav AB, Kumar K and Misra A. Pharmacokinetic of PLA microparticles in Rhesus monkeys. XVI International conference on Bioencapsulation-2008, Dublin, IRELAND.
◊ Verma RK and Misra A. Inhalable poly lactide particles as drug carrier against tuberculosis (Oral presentation). NIPER Second Winter school 2009–Nanotechnology in advance Drug delivery, National Institute of Pharmaceutical Education and Research(NIPER), Mohali, INDIA.
◊ Verma RK and Misra A. Serum, tissue and intracellular concentrations following pulmonary delivery in rhesus macaques (Oral) International Symposium on -Optimizations of Inhaled Tuberculosis Therapies and Implications for Host-Pathogen Interactions-2009 New Delhi INDIA.
◊ Misra A, Yadav AB, Singh AK, Verma RK, Mohan M. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work. A International Symposium on -Optimizations of Inhaled Tuberculosis Therapies and Implications for Host-Pathogen Interactions-2009 New Delhi INDIA.
◊ Sharma R, Muttil P, Yadav AB, Verma RK, Singh AK, Mohan M, Misra A. Serendipitous activation of mouse and human macrophages infected with Mycobacterium tuberculosis on treatment with inhalable microparticles. An International Symposium on -Optimizations of Inhaled Tuberculosis Therapies and Implications for Host-Pathogen Interactions-2009 New Delhi INDIA.
◊ Sharma R, Muttil P, Yadav AB, Verma RK, Singh AK, Devi HK, Mohan M, Arora SK, Sen H, Sinha S, Suryakumar J, Modak V, Vineeth R, and Misra A Preclinical safety, efficacy and mechanism of action of inhaled microparticles containing anti-tuberculosis agents. Third indo-Japanese International Joint Symposium on overcoming interactable infectious disease prevalent in Asian countries-2010, Dec-13-14 2010, Tokyo University of Science, Tokyo, JAPAN.
◊ Verma RK, Pandya S, Khare P, Dube A, Verma PRP and Misra A. Nitric oxide releasing PLGA nanoparticles: evaluation of antileishmanial activity. NanoBio-2012 Second International Conference on Nanotechnology and Molecular Medicine at Biomedical interface, kochi, INDIA.
◊ Singh AK, Verma RK, Heikham KD, Mohan M, Agrawal AK, Gupta A and Misra A. Inhalable particles for value added drug delivery in tuberculosis. INDO-US joint Symposium on Nanomedicine: Propects and Challenges,14-15November 2011, Institute of Chemical Technology, Hydrabad, INDIA.
◊ Singh Ak, Mohan M, Agrawal AK, Verma RK, Misra A, Gupta UD and Gupta P Quantitative PCR for persistent bacterial DNA following pulmonary delivery of microparticles Conference on Inhaled therapy for tuberculosis (1-3 Oct 2013), Tokyo University of Science, Tokyo JAPAN.
CONTACT INFORMATION :
Tel: 0172 - 2210075
Email Id : rahulverma(at)inst(dot)ac(dot)in
Office Address :
Institute of Nano Science & Technology
Habitat Centre, Sector - 64, Phase X, Mohali